A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This single-dose, randomized, double-blind, double-dummy, placebo-controlled,
positive-controlled four-way crossover study will evaluate the effect of a single dose of
danoprevir with low-dose ritonavir on the QC/QTc interval in healthy volunteers. Subjects
will be randomly assigned to one of four sequences with treatments of A: therapeutic dose of
danoprevir plus ritonavir (DNV/r), B: supratherapeutic dose of DNV/r, C: moxifloxacin and D:
placebo, with a washout period of at least 7 days between treatments.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Fluoroquinolones Lactams Moxifloxacin Norgestimate, ethinyl estradiol drug combination Ritonavir